Completed OBSERVATIONAL NCT02135757

Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients

A Phase IV Multicenter Trial to Evaluate Real-world Health Outcomes, Economic Impact and Resistance Mechanisms of Panitumumab in the Treatment of Patients With Chemotherapy-refractory Metastatic Colorectal Cancer

Sponsor: PeriPharm

Conditions Colorectal Cancer Metastatic

Updated 7 times since 2017 Last updated: Mar 29, 2018 Started: Aug 31, 2014 Primary completion: Mar 31, 2018 Completion: Mar 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Colorectal Cancer Metastatic and is currently completed. PeriPharm leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Status: Active Not Recruiting → Completed · Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Active Not Recruiting NA

First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PeriPharm
Personalized Medicine Partnership for Cancer

Data source: PeriPharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Greenfield Park, Canada
• Montreal, Canada